Research Center for Traditional Chinese Medicine Modernization
Recognized for Advancing Quality Control Authentication and Profiling
MILFORD, Mass.--(BUSINESS WIRE)--Oct. 21, 2015--
Waters Corporation (NYSE: WAT) today welcomed the Shanghai Institute of
Materia Medica’s (SIMM) Research
Center for Modernization of Traditional Chinese Medicine under the
direction of Dr.
De-an Guo into the Waters
Centers of Innovation (COI) Program. The Research Center plays a
leading role in the effort to develop standardized methods for analyzing
the authenticity and compositional integrity of traditional medicines
and bring them into compliance with quality standards instituted by the China
Foodand Drug Administration (CFDA).
This Smart News Release features multimedia. View the full release here:
Today in Shanghai, Waters welcomed Dr. De-an Guo and the Shanghai Institute of Materia Medica into the Waters Centers of Innovation Program. Pictured (l. to r.) are Professor Yang Ye, Deputy Director of the Shanghai Institute of Materia Medica; Dr. De-an Guo, Director - Research Center for Modernization of Traditional Chinese Medicine, Shanghai Institute of Materia Medica; Mike Harrington, Vice President, European & Asia Pacific Operations, Waters Corporation; and Eric Fotheringham, Director – Waters Centers of Innovation Program, Waters Corporation. (Photo: Business Wire)
Said Yang Ye, Deputy Director of Shanghai Institute of Materia Medica,
“We are pleased to have our TCM Research Center honored by Waters for
the Centers of Innovation Program, the first in China. This is a
wonderful opportunity for the Center and Waters to work closely together
to tackle the holistic analysis of the complex Chinese herbal system.”
On hand to congratulate Dr. Guo and his team was Dr. Mike Harrington,
V.P. Asia/Pacific Operations, Waters Division. “We could not be more
excited to be working with Dr. Guo and his fellow researchers at the
Shanghai Institute of Materia Medica,” said Harrington. “The work of the
Institute and the Research Center is vital to the efforts to globalize
Traditional Chinese Medicine and enlist it in the fight against disease
and in the quest to improve human health.”
Said Eric Fotheringham, Director – Waters Centers of Innovation Program,
"We are particularly pleased to welcome Dr. Guo and his team into the
Waters Centers of Innovation Program, as they are the first COI Program
partner focused upon the challenges of characterizing TCM related raw
materials and manufactured products."
In his remarks delivered at Wednesday’s ceremony, Brian Smith, V.P. –
Mass Spectrometry Operations, Waters Division, said, “Through our
partnership with Dr. Guo, and by combining analytical technology with
great science, we are helping one another advance TCM and bring it onto
a global stage.”
Now that the CFDA regulates Traditional Chinese Medicines and related
herbal supplements, Dr. Guo’s Research Center for Modernization of
Tradition Chinese Medicine is tasked with developing standardized
quality control test methods for herbal medicines and bringing them into
routine use. Currently, many TCM quality standards are mostly based on
the presence of a single marker in a sample, but as Dr. Guo points out,
this approach is not without its drawbacks, since an unscrupulous
manufacturer could simply add that single marker into the formulation to
falsify the results and make it look like it is something it really
isn’t. "We’re now using UPLC to profile the whole chemical composition,
and to quantify the multiple active markers, not just a single marker,"
said Dr. Guo. "By taking a more holistic approach to quality control,
including fingerprint profiling, multi-component quantification, testing
for pesticides, heavy metals, and microbial contaminations we can
identify whether it is the true herb and attest to its quality."
To fulfill its mission, the Center uses a variety of state-of-the art
instruments in addition to the Waters® ACQUITY®
UPLC® System. They include the Waters ACQUITY
QDa® Mass Detector, the ACQUITY
UPC2® Convergence Chromatography™ system, and a Xevo®
G2-XS QTof mass spectrometer. The Center also relies on modern
informatics platforms, such as the Waters
UNIFI® Scientific Information System to maintain high
Waters officially saluted the work of Dr. Guo and Research Center for
TCM Modernization with a ceremony and three-day conference organized in
part and sponsored by the Waters Centers of Innovation Program. The 2015
Shanghai International Conference on Traditional Chinese Medicine and
Natural Medicineis featuring presentations and a panel discussion
by more than three dozen experts in TCM.
Asked what the recognition means to him, Dr. Guo said, “It’s really an
honor and a privilege for Waters to take so much interest in the work we
do. I’m looking at this as an opportunity to deepen our collaboration
and working together on quality monographs for Chinese herbal medicines
for the Chinese pharmacopoeia and others, such as United States
Pharmacopoeia and European Pharmacopoeia.”
Dr. Guo, as Editor-in-Chief, recently co-authored
an article in the World Journal of Traditional Chinese Medicine in
which the authors document the progress of China’s TCM modernization
efforts and the challenges it still faces.
About Traditional Chinese Medicine
For more than 2,000 years, medicines derived from natural sources have
been a staple of Chinese medical practice. In the late 1990’s, the
Chinese government initiated an effort to modernize TCM. Broadly
defined, this effort intends to push for the acceptance and integration
of Chinese medical philosophy into western medical practice and seek
regulatory approval of herbal medicines to treat disease.
The effort, involving government, pharmaceutical industry and academic
scientists, has resulted in the adoption of over 50 TCM quality
monographs by the United States or European Pharmacopeias. Several TCM
products are also in mid-to-late-stage clinical trials in the U.S. and
About the Shanghai Institute of Materia Medica, Chinese Academy of
The Shanghai Institute of Materia Medica (SIMM) at the Chinese Academy
of Sciences emerged from the Institute of Materia Medica of the Peking
Academy of Sciences, founded in 1932. By combining basic and applied
research in chemistry and biological disciplines, SIMM carries out
modern drug discovery. SIMM is also involved in the discovery of new
therapeutic targets and carries out comprehensive pre-clinical
evaluation of drug candidates, while also promoting commercialization,
thereby playing a key role in building China's drug innovation
capabilities. For more information, visit http://www.simm.cas.cn.
About Waters Centers of Innovation Program
Established in 2010, Waters
Centers of Innovation Program recognizes accomplished scientists and
their institutions for research in the fields of the health sciences,
pharmaceuticals, chemical materials, food and environmental chemistry,
mass spectrometry and separations science. By partnering with leading
scientists and connecting them with experts in mass spectrometry and
separations science, Waters endeavors to bring about inspired thinking
that converts ideas into reality.
The participants in the Waters Centers of Innovation Program include: Professor
Ganesh Anand, National University of Singapore; Professor
Luiz Claudio Cameron, UniRio, Brazil; Professor
David Clemmer, Indiana University; Professor
Daniel Tsun-Yee Chiu, Chang Gung University; Dr.
Joseph Dalluge, University of Minnesota; Dr. Petur Weihe Dalsgaard, University
of Copenhagen; Professor
Marcos Eberlin, University of Campinas, Brazil; Professor
Chris Elliott, Queen’s University Belfast; Professor
John Engen, Northeastern University; Professor
Albert J. Fornace, Jr., Georgetown Lombardi Comprehensive Cancer
David Goodlett and Dr.
Maureen Kane, University of Maryland; Professor
De-an Guo, Shanghai Institute of Materia Medica; Dr.
Frank Gonzalez, National Cancer Institute; Dr. Carlo R. Largiadèr,
Dr. Jean-Francois DuFour and Dr. Martin Fiedler, Inselspital
University Hospital, Bern, Switzerland; Professor
Julie Leary, University of California – Davis; Professor
Amit Kumar Mandal, St. John’s Research Institute, Bangalore, India; Professor
John McLean, Vanderbilt University; Professor
Arthur Moseley, Duke University; Professor
Jeremy Nicholson, Imperial College London; Dr.
Devin Peterson, University of Minnesota; Associate
Professor Jessica Prenni, Colorado State University; Dr. Serge
Institute of Health Sciences; Dr.
Ryan Rodgers, Future Fuels Institute, Florida State University; Professor
Pauline Rudd, National Institute for Bioprocessing Research and
James Scrivens, University of Warwick; Professor
Vladimir Shulaev, University of North Texas; Dr.
Norman Smith, Kings College London; Professor
Sarah Trimpin, Wayne State University; Professor
Bert van Bavel, Örebro University; Caroline
West and Eric Lesselier, University of Orleans, Orleans, France; and Professor
Vicki Wysocki, The Ohio State University.
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE: WAT) develops and manufactures advanced
analytical and material science technologies for laboratory dependent
organizations. For more than 50 years, the company has pioneered a
connected portfolio of separations science, laboratory information
management, mass spectrometry and thermal analysis systems.
Waters, ACQUITY, UPLC, UPC2, Xevo, QDa, UNIFI and Convergence
Chromatography are trademarks of Waters Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151021005950/en/
Source: Waters Corporation
Brian J. Murphy, +1-508-482-2614